MOTS-c is a tiny peptide, just 16 amino acids long, encoded within the mitochondrial genome and increasingly recognized as a powerful regulator of metabolism, exercise adaptation, and aging. First identified in 2015 by a team at the University of Southern California, MOTS-c has since drawn attention from researchers in fields ranging from endocrinology and cardiology to neuroscience and immunology. Despite the breadth of animal and cell-based evidence linking it to improvements in insulin sensitivity, physical performance, and age-related disease, no clinical application in humans exists yet. The science behind it, though, is genuinely fascinating and worth understanding.
What MOTS-c Actually Is
MOTS-c stands for “mitochondrial open reading frame of the 12S rRNA type-c.” It belongs to a family of signaling molecules called mitochondrial-derived peptides, which are small proteins encoded not in the cell’s main nuclear DNA but in the much smaller genome that lives inside mitochondria. The peptide is produced from a short open reading frame hidden within the gene for 12S ribosomal RNA, a stretch of mitochondrial DNA that was long assumed to serve only a structural role in making ribosomes.1PubMed Central. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation Its discovery suggested that mitochondrial DNA carries far more coding potential than previously thought.
An unusual feature of MOTS-c is that it cannot actually be translated inside the mitochondria themselves. If it were, the mitochondrial genetic code would place a stop signal right at the start. Instead, the RNA transcript is exported out of the mitochondria and translated in the cytoplasm using the standard genetic code, producing a functional 16-amino-acid peptide.2Cell Metabolism. MOTS-c Is a Mitochondrial-Encoded Regulatory Peptide that Regulates Insulin Sensitivity and Dietary Energy Homeostasis MOTS-c is not alone in this family. Other mitochondrial-derived peptides, including humanin and a set called SHLP1 through SHLP6, have been found encoded in the 16S rRNA region and are also linked to metabolic regulation and age-related diseases.3Diabetes & Metabolism Journal. Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases
Sequence comparisons across 14 species show that MOTS-c is highly conserved, particularly in its first 11 amino acid positions. Several of those residues appear to have been shaped by positive natural selection, meaning evolution has actively favored changes at specific sites, while others are under purifying selection, meaning evolution has worked to keep them unchanged.4Cell Metabolism. MOTS-c Is a Mitochondrial-Derived Peptide Associated with Equine Exercise That kind of dual selective pressure hints that MOTS-c is not just a relic but plays an active and finely tuned biological role.
How MOTS-c Works Inside Cells
The primary mechanism through which MOTS-c exerts its effects involves a chain reaction that ultimately switches on AMPK, one of the cell’s master energy sensors. When MOTS-c enters cells, it interferes with the folate cycle, a biochemical pathway involved in one-carbon metabolism. That disruption reduces levels of a molecule called 5-methyltetrahydrofolate and, downstream, blocks a step in the production of purines, the building blocks of DNA and RNA. As purine synthesis stalls, an intermediate called AICAR builds up inside the cell. AICAR happens to be a well-known activator of AMPK, the same energy-sensing enzyme that drugs like metformin target.5PubMed Central. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging Skeletal muscle appears to be the primary tissue where these actions play out.6PubMed Central. The Mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
AMPK activation is essentially the cell’s way of flipping from “storage mode” to “burn-and-repair mode.” It ramps up glucose uptake, increases fat oxidation, and dampens energy-expensive processes. That MOTS-c achieves this through a pathway parallel to metformin is one reason researchers are so interested in it as a potential metabolic therapy.
But MOTS-c does something that most small signaling peptides cannot: it physically moves into the cell nucleus. A 2018 study demonstrated that under metabolic stress, such as glucose restriction, MOTS-c translocates from the cytoplasm to the nucleus in an AMPK-dependent manner. Once there, it interacts with transcription factors like NRF2 and regulates a broad range of genes, including those involved in antioxidant defense.7PubMed Central. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress This is a form of retrograde signaling: a message sent from the mitochondria back to the nucleus to change how the cell responds to stress. It reframes MOTS-c not just as a metabolic booster but as a direct line of communication between the mitochondrial and nuclear genomes.
Insulin Sensitivity and Fat Metabolism
The metabolic effects of MOTS-c were the first to be characterized and remain the most extensively studied. In the original 2015 paper, researchers showed that giving MOTS-c to mice significantly improved the rate at which their muscles cleared glucose from the blood in response to insulin, a measure of insulin sensitivity. Since roughly 70 to 85 percent of insulin-stimulated glucose disposal occurs in skeletal muscle, the peptide’s insulin-sensitizing effects appear to be rooted there.8Cell Metabolism. MOTS-c Is a Mitochondrial-Encoded Regulatory Peptide that Dictates Metabolic Homeostasis
These effects extend to the liver, where MOTS-c treatment dramatically reduced fat accumulation in mice fed high-fat diets. The peptide also prevented both age-dependent and diet-induced insulin resistance. In cell studies, MOTS-c-treated cells showed increased levels of molecules associated with fat breakdown and reduced levels of long-chain fatty acids, supporting the idea that MOTS-c pushes the body toward burning fat rather than storing it.9Cell Metabolism. MOTS-c Is a Mitochondrial-Derived Peptide Regulating Survival and Insulin Resistance Mice given MOTS-c while eating a high-fat diet gained less weight, spent more energy, and had lower circulating insulin levels, further suggesting improved metabolic efficiency.10PubMed Central. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity
Beyond simple fat reduction, MOTS-c has shown protective effects against nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease. Both long-term preventive and short-term therapeutic MOTS-c treatment alleviated liver fat buildup, inflammation, cell death, and fibrosis in mice fed a NASH-promoting diet, and the peptide reversed the mitochondrial metabolic deficiency that NASH typically causes.11PubMed. The mitochondrial genome-encoded peptide MOTS-c interacts with Bcl-2 to alleviate nonalcoholic steatohepatitis progression
The Exercise Connection
One of the more striking findings about MOTS-c is its relationship to physical activity. Endogenous MOTS-c, meaning the peptide your own body makes, increases substantially during and after exercise. In a study of healthy young men who exercised on a stationary bicycle, MOTS-c levels in skeletal muscle surged roughly 12-fold after exercise and remained elevated for hours. Circulating levels in the blood also rose about 1.5 to 1.6 times during and immediately after the workout before returning to baseline after four hours of rest.12Nature Communications. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis This pattern suggests that MOTS-c is part of how muscles adapt to physical stress.
The evidence goes both directions. Not only does exercise raise MOTS-c, but giving MOTS-c to animals improves exercise performance. Young mice treated with daily MOTS-c injections for about two weeks showed significantly better running capacity and power output on a treadmill. The effect appears to be specifically about physical endurance and coordination, not raw strength: grip strength and cognitive maze performance were unchanged. In rodents, four to eight weeks of voluntary wheel running increased MOTS-c protein in several leg muscles by roughly 1.5 to 5 times, and those elevated levels persisted for four to six weeks even after the animals stopped exercising.13PubMed Central. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose Even a single dose of MOTS-c improved acute running time and distance in untrained mice by about 12 and 15 percent, respectively.
These findings have prompted the idea that MOTS-c may function as an “exercise mimetic,” a molecule that reproduces at least some of the metabolic benefits of physical activity. That framing is not quite right, since MOTS-c does not replicate the full physiological cascade of actual exercise, but the overlap in downstream AMPK signaling and metabolic adaptation is real and meaningful.14PubMed Central. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)
Protecting Muscle From Wasting
MOTS-c’s role in muscle goes beyond exercise performance. Muscle wasting, whether caused by aging, obesity, immobilization, or chronic illness, is a major health concern and has few effective treatments. In mice fed a high-fat diet, MOTS-c reduced the expression of myostatin, a protein that acts as a brake on muscle growth. By lowering myostatin levels, MOTS-c helped protect muscle cells from the atrophy that typically accompanies obesity-driven insulin resistance.15PubMed Central. MOTS-c reduces myostatin and muscle atrophy signaling
In a separate study modeling immobilization-induced atrophy, which is what happens when a limb is immobilized in a cast, untreated mice lost about 15 percent of their muscle mass. Mice given MOTS-c lost only about 5 percent. The mechanism appears to involve MOTS-c suppressing the infiltration of fat into muscle tissue, a pathological process common across many types of muscle atrophy, including those caused by aging, cancer, and nerve damage.16PubMed Central. Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration Because lipid accumulation in muscle tissue is such a common feature across atrophy types, the researchers suggested MOTS-c treatment could be broadly applicable.
Effects on Bone
The skeleton is another tissue where MOTS-c appears to have meaningful effects. Healthy bone is maintained by a balance between osteoblasts (cells that build bone) and osteoclasts (cells that break it down). Research has shown that MOTS-c promotes osteoblast proliferation, differentiation, and mineralization while inhibiting osteoclast formation.17PubMed Central. Role of MOTS-c in the regulation of bone metabolism
In a mouse model of postmenopausal osteoporosis, MOTS-c treatment significantly reduced bone loss as measured by micro-CT imaging. The mechanism again traces back to AMPK: MOTS-c increased AMPK activity, which in turn suppressed the differentiation of osteoclasts triggered by a signaling molecule called RANKL. When the researchers blocked AMPK with an inhibitor, MOTS-c’s bone-protective effects were partially reversed, confirming that AMPK signaling is central to this benefit.18PubMed. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation
Fat Tissue Remodeling and Heat Production
MOTS-c’s influence on adipose (fat) tissue goes beyond simply preventing fat accumulation. It appears to actively change the type of fat the body maintains. In animal studies, MOTS-c dramatically increased the activity of brown fat, the metabolically active tissue that burns calories to generate heat. It also promoted “browning” of white fat, the ordinary storage fat, essentially converting some of it into a more metabolically active form.19PubMed Central. Mitochondrial-Derived Peptide MOTS-c Increases Adipose Thermogenic Activation to Promote Cold Adaptation
In a model of metabolic dysfunction caused by ovarian hormone loss, simulating menopause in mice, MOTS-c treatment increased brown fat activation and reduced the inflammatory invasion that normally accumulates in white fat tissue after estrogen drops. This contributed to lower circulating fatty acid levels and less fat accumulation in the liver.20PubMed. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction The convergence of reduced white fat, activated brown fat, and lower liver fat suggests that MOTS-c reshapes the body’s overall fat economy rather than just shrinking one depot.
Cardiovascular and Immune Effects
In a rat model of vascular calcification, a condition where calcium deposits stiffen and damage blood vessel walls, MOTS-c treatment improved heart abnormalities and reduced the calcification itself by activating the AMPK pathway. The peptide also lowered the expression of receptors involved in vascular constriction and remodeling.21Cardiorenal Medicine. Mitochondrial-Derived Peptide MOTS-c Attenuates Vascular Calcification and Secondary Myocardial Remodeling via Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway This is early-stage evidence, but the direction is consistent with the broader theme of MOTS-c dampening pathological processes driven by metabolic dysfunction.
On the immune side, MOTS-c has shown antimicrobial and anti-inflammatory properties. In mice challenged with methicillin-resistant Staphylococcus aureus (MRSA), MOTS-c significantly improved survival and reduced bacterial loads. It lowered levels of pro-inflammatory signaling molecules while boosting an anti-inflammatory one, and it enhanced the bacteria-killing capacity of macrophages, the immune cells that engulf and destroy pathogens.22PubMed. MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA The peptide’s effect was not about juicing up inflammation but about rebalancing it, curbing the runaway inflammatory response that often causes more damage than the infection itself.
Neuroprotection and Brain Injury
MOTS-c’s anti-inflammatory and stress-protective properties extend to the brain. In mouse models of traumatic brain injury, MOTS-c treatment improved memory, learning, and motor function impairments caused by the injury.23PubMed Central. Neuroprotective Mechanism of MOTS-c in TBI Mice: Insights from Integrated Transcriptomic and Metabolomic Analyses In models of sepsis-induced brain damage, MOTS-c reduced mortality, decreased brain tissue damage, lowered neuroinflammation, and strengthened the blood-brain barrier, the selective membrane that normally shields the brain from toxins and immune cells circulating in the blood.24PubMed. A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier’s ultrastructure
There are also hints that MOTS-c may be relevant to neurodegenerative conditions. A modified, cell-penetrating version of MOTS-c enhanced memory formation and consolidation in healthy mice and ameliorated memory deficits caused by beta-amyloid fragments, the protein clumps associated with Alzheimer’s disease. The mechanism appeared to involve suppressing the activation of astrocytes and microglia, the brain’s resident inflammatory cells, and reducing their output of pro-inflammatory molecules.25PubMed. Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates Aβ(1-42)- or LPS-Induced Memory Impairment through Inhibiting Neuroinflammation This is still the earliest stage of preclinical work, but the consistency of the anti-inflammatory and stress-protective theme across tissues is worth noting.
MOTS-c as a Biomarker
Beyond its potential therapeutic use, circulating MOTS-c levels may carry diagnostic information. In a study of people with type 2 diabetes who had undergone coronary artery revascularization, those with MOTS-c concentrations below 167 nanograms per milliliter had a roughly four-fold higher risk of major adverse cardiac events compared to those with higher levels, especially when combined with high platelet reactivity.26PubMed. β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease Low MOTS-c may signal a metabolically stressed state in which mitochondria are underperforming.
In children with type 1 diabetes, MOTS-c levels were lower than in healthy children, but researchers found no association between those levels and early markers of diabetic kidney disease such as microalbuminuria or declining filtration rates. The peptide’s reduction in these patients seems to reflect the broader metabolic disturbance of diabetes rather than serving as a specific kidney-damage indicator.27Journal of Clinical Research in Pediatric Endocrinology. Could MOTS-c Levels in Children with Type 1 Diabetes Mellitus Be an Indicator for Early Diabetic Kidney Disease?
A similar pattern has emerged in women with polycystic ovary syndrome (PCOS). Serum MOTS-c levels were negatively correlated with total testosterone and total cholesterol and positively correlated with physical activity scores. The associations with testosterone and cholesterol remained significant even after adjusting for age and body mass index, suggesting MOTS-c tracks with aspects of metabolic and hormonal health independently of body weight.28Scientific Reports. Reduced serum and skeletal muscle MOTS c levels in women with polycystic ovary syndrome are associated with mitochondrial dysfunction
Why MOTS-c Is Not Yet a Treatment
With such a wide range of preclinical benefits, it is reasonable to wonder why MOTS-c has not already become a drug. The honest answer is that virtually all of the evidence comes from cell cultures and animal models. No effective method for applying MOTS-c in human clinical practice has been developed.29PubMed Central. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation The peptide is small and would be rapidly degraded in the digestive tract, making an oral pill impractical without chemical modifications. Most animal studies use intraperitoneal injection, a route that does not translate neatly to outpatient human use. And while MOTS-c’s effects in mice are impressive, dose-response relationships, long-term safety profiles, and pharmacokinetics in humans remain largely uncharted.
There is also the question of specificity. MOTS-c acts through AMPK, a pathway involved in an enormous range of cellular processes. Activating AMPK in the right tissue at the right time may produce benefits; doing so broadly and continuously could have unintended consequences. Metformin, the diabetes drug that also works partly through AMPK, is generally safe but carries its own side-effect profile built up over decades of clinical experience. MOTS-c has none of that track record yet.
Despite those hurdles, the peptide remains one of the most intriguing molecules to come out of mitochondrial biology in the past decade. It sits at the intersection of exercise physiology, metabolic disease, aging, and immune regulation, connected to all of them through a central pathway. Researchers continue to work on modified analogs that might be more stable and bioavailable, and the growing understanding of how MOTS-c moves from mitochondria to the nucleus opens new avenues for designing interventions. For now, the most reliable way to boost your own MOTS-c is also the simplest: regular exercise raises it consistently and keeps muscle levels elevated even during weeks of rest.